In this phase III study, the use of modified FOLFIRINOX resulted in a significantly better overall survival and disease-free survival (DFS) compared with gemcitabine alone. DFS served as the primary endpoint of the study. These data were the first to demonstrate such a profound benefit with the use of adjuvant chemotherapy, Philip says. Notably, there was no use of radiation therapy in the study. Watch here . . .